Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Intensified competition from Eli Lilly's Zepbound and compounded semaglutide products has led to flat prescriptions, underwhelming trial results, and a 25% share drop in March 2025.